Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.
Esperion Therapeutics develops and commercializes therapies for cardiometabolic and rare/orphan diseases, with a commercial focus on oral, once-daily, non-statin LDL-C treatments for patients at risk for cardiovascular disease. Company news commonly covers NEXLETOL bempedoic acid data, CLEAR Outcomes analyses, dyslipidemia guideline developments, financial results, business updates, and material agreements.
Esperion's news also reflects portfolio expansion through its completed acquisition of Corstasis Therapeutics and Enbumyst bumetanide nasal spray, an FDA-approved loop diuretic for edema associated with congestive heart failure and hepatic or renal disease in adults. Additional recurring topics include ACLY biology, product commercialization, pipeline work in Primary Sclerosing Cholangitis and renal diseases, and governance or capital-structure matters.
Esperion (NASDAQ: ESPR) reported FY2025 total revenue of $403.1M (21% Y/Y) and Q4 revenue of $168.4M (144% Y/Y). U.S. net product revenue grew ~38% Y/Y to $159.6M for FY2025. The company announced an agreement to acquire Corstasis and Enbumyst™, and strengthened patent settlements and payer coverage.
Key financials: Q4 U.S. product sales $43.7M, collaboration revenue driven by a $90M Otsuka payment, FY net loss $22.7M, cash $167.9M, and 2026 operating expense guidance of $225M–$255M.
Esperion (NASDAQ: ESPR) agreed to acquire Corstasis to add Enbumyst™ (bumetanide nasal spray), the first FDA‑approved intranasal loop diuretic (approved Sept 2025), for edema associated with CHF, hepatic and renal disease. The deal includes a $75 million upfront cash payment, up to $180 million in milestones, low double‑digit royalties, and expected close in Q2 2026.
Esperion will finance the transaction via existing credit facilities and royalty monetization and expects the product to leverage its cardiovascular commercial infrastructure to drive double‑digit revenue growth and expand its portfolio.
Esperion (NASDAQ: ESPR) will report Q4 and full-year 2025 financial results before the market opens on Tuesday, March 10, 2026. Management will host a live audio webcast at 8:00 a.m. ET to discuss results and business updates.
Webcast access and a replay will be available on the company's investor site, with the replay archived for approximately 90 days.
Esperion (NASDAQ: ESPR) will participate in the 2026 Citizens Life Sciences Conference on March 11, 2026, presenting at 8:25 a.m. ET. The presentation will be webcast live and accessible via the company’s investor and media website. A replay will be available about two hours after the call and archived for approximately 90 days.
Esperion (NASDAQ: ESPR) announced a settlement with Alkem Laboratories resolving patent litigation over NEXLETOL and NEXLIZET. Under the agreement, Alkem agreed not to market generic versions in the U.S. prior to April 19, 2040, subject to customary limited exceptions.
Litigation against four other ANDA filers remains pending, and there is no assurance those cases will prevent earlier generic entry.
Esperion (NASDAQ: ESPR) announced on February 10, 2026 the grant of 40,200 restricted stock units (RSUs) to 11 newly hired employees under its 2017 Inducement Equity Incentive Plan pursuant to NASDAQ Rule 5635(c)(4).
The RSUs vest 25% at one year, with the remaining 75% vesting in twelve equal quarterly installments, subject to continued employment and plan terms.
Esperion (NASDAQ: ESPR) provided preliminary full‑year 2025 results and a business update on Jan 11, 2026, and outlined its long‑term Vision 2040 growth strategy. Key preliminary figures: U.S. net product sales $156–$160M (+35%–38% vs 2024), total revenue $400–$408M (+20%–23% vs 2024; ~55%–59% excl. one‑time milestones), and cash & cash equivalents ≈ $168M at year‑end 2025. Q4 retail prescription equivalents rose 34% Y/Y and 11.3% Q/Q. Company expects 2026 operating expenses $210–$245M and announced R&D and global commercial expansion, including IND‑enabling work for ESP‑2001 (PSC) and plans for oral triple combination lipid therapies targeted for commercialization in 2027.
Esperion (NASDAQ: ESPR) will present at J.P. Morgan’s 44th Annual Healthcare Conference on Wednesday, January 14, 2025 with a presentation and fireside chat starting at 2:15 p.m. PT / 5:15 p.m. ET. The event will be available via a live webcast on the company investor website.
A replay will be posted approximately two hours after the call and archived on the company website for about 90 days. Esperion is a commercial-stage biopharmaceutical company marketing two oral, once-daily non-statin LDL-C therapies, with global approvals in >40 countries and a pipeline focused on ACLY biology and treatments for primary sclerosing cholangitis and renal diseases.
Esperion (NASDAQ: ESPR) said bempedoic acid was recommended by the 2025 ACC Scientific Statement for LDL-C lowering in adults with peripheral artery disease (PAD) and diabetes on maximally tolerated statins.
The statement endorses LDL-C reduction >50% and goal 55 mg/dL using therapies with proven cardiovascular benefit, listing bempedoic acid alongside high-intensity statins, ezetimibe, and PCSK9 inhibitors. Analysis cited from CLEAR Outcomes reported a versus placebo. Product indications and safety risks for NEXLIZET and NEXLETOL are reiterated, including hyperuricemia and tendon rupture warnings.
Esperion (NASDAQ: ESPR) announced inducement equity grants dated December 4, 2025 under its 2017 Inducement Equity Incentive Plan. The company granted an aggregate of 380,000 non‑qualified stock options and 435,536 restricted stock units (RSUs), with John Harlow, the new Chief Commercial Officer, receiving 380,000 options and 424,536 RSUs. The option exercise price is $3.79, equal to the December 4, 2025 closing share price.
Vesting: 25% at the one‑year anniversary of each recipient’s vesting commencement date, then the remaining 75% in twelve equal quarterly installments, subject to continued employment and plan terms.